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Abstract
Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme,
hypoxanthine guanine phosphoribosyl transferase (HPRT). LND gives rise to severe neurological anomalies including mental
retardation, dystonia, chorea, pyramidal signs and a compulsive and aggressive behavior to self injure. The neurological
phenotype in LND has been shown to reflect aberrant dopaminergic signaling in the basal ganglia, however there are little
data correlating the defect in purine metabolism to the neural-related abnormalities. In the present studies, we find that
HPRT-deficient neuronal cell lines have reduced CREB (cAMP response element-binding protein) expression and intracellular
cyclic AMP (cAMP), which correlates with attenuated CREB-dependent transcriptional activity and a reduced
phosphorylation of protein kinase A (PKA) substrates such as synapsin (p-syn I). Of interest, we found increased expression
of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA
restored cAMP/PKA signaling. Furthermore, reconstitution of HPRT expression in mutant cells partly increased cAMP
signaling synapsin phosphorylation. In conclusion, our data show that HPRT-deficiency alters cAMP/PKA signaling pathway,
which is in part due to the increased of PDE10A expression and activity. These findings suggest a mechanistic insight into
the possible causes of LND and highlight PDE10A as a possible therapeutic target for this intractable neurological disease.
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Introduction
Mutations in the gene encoding the purine biosynthetic enzyme
Hypoxanthine phosphoribosyltransferase (HPRT) (IMP: pyrophos-
phatePhosphoribosyltransferase;EC2.4.2.8) leads tobothmetabolic
and neurological defects that can lead to Lesch-Nyhan Disease
(LND). The impairment in purine metabolism associated with LND
has been well characterized and recognized clinically as hyperurice-
mia, which can be treated with allopurinol. However, other features
ofLNDsuchasdystonia, choreoathetosis,mental retardationand the
hallmark neurobehavioral trait of compulsive self-mutilation are
mostly untreatable [1]. Post-mortem analysis of LND patients and
studies of HPRT-knock out (KO) mice have indicated that
dysfunctional dopaminergic signaling in the midbrain and the basal
ganglia may cause this disease phenotype, although themechanisms
underlying the pathogenesis of LND are not well understood [2].
HPRT-deficiencyhasbeen shown toalter theexpressionof anumber
of transcription factors and key signaling components that are
necessary for neuronal development, however these data still do not
fully elucidate the relationship between the defect in the purine
metabolism and the neural phenotype associated with LND [3–6].
For the current study,wehypothesize that alteredpurinemetabolism
due to HPRT-deficiency affects the homeostasis of signaling
pathways related to purine metabolic functions, including ubiqui-
tously expressed secondmessengers such as cyclic AMP (cAMP).We
have previously shown that HPRT-deficiency leads to the dysregu-
lation of microRNA-181a (miR-181a) [7], here we have carried out
supplemental analysis of miR-181a target genes using gene ontology
analysis, and uncovered genes implicated in the regulation cAMP/
PKA signaling pathway.Our data show thatHPRT-deficiency leads
to a reduced expression of CREB, blunted cAMP production and
reduced phosphorylation of PKA substrates, including phospho-
synapsin, in HPRT-deficient MN9D neuronal cell lines. Further-
more, we identified increased PDE10 expression inHPRT-deficient
cells which contributes at least in part to the decreased cAMP/PKA
signaling. Overall, our data provide a mechanism by which blunted
cAMP/PKA signaling and phosphorylation of PKA substrates, such
as synapsin,maycontribute to theneurological phenotypeassociated
with HPRT-deficiency and also highlights PDE10 as a potential
target for LND.
Materials and Methods
Cells
Human SH-SY5Y cells (ATCC) were maintained in a 1:1
mixture of Eagle’s minimum essential medium and F12 Medium
(Gibco, Carlsbad CA) containing 10% fetal bovine serum (FBS)
and 50 mg/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA)
in 5% CO2. Parent HPRT positive cells and HPRT deficient
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mutant MN9D cells were obtained from Dr. Jinnah (Emory
University, Atlanta, GA) [8]. MND9 and Human embryonic
kidney (HEK, ATCC) 293 cells were cultured at 37uC under in
5% CO2, in DMEM medium supplemented with 10% FBS,
50 mg/ml penicillin/streptomycin. We also selected human
control (CTL), HPRT-deficient fibroblasts consistent with partial
(LNV) or complete (LND) HPRT-enzymatic activity. LNV and
LND phenotypes represent mildly and severely affected patients,
respectively. These fibroblasts were also kindly provided by Dr.
Jinnah (Emory University, Atlanta, Ga), and grown in DMEM
medium supplemented with 10% FBS, 50 mg/ml penicillin/
streptomycin.
Figure 1. Reduction of CREB expression in HPRT-deficiency. Reduction of CREB expression in HPRT-deficient human SH-SY5Y (A & B) and
mouse MN9D (D & F) cells lines. Cells were then stimulated with DMSO (as control) or Forskolin (see methods). Immuno-blot as well as the
quantification of protein through densitometry analysis show impaired expression of CREB in response to forskolin. The asterisks (*) represent
statistical significance between forskolin treated cells (p,0.05, t-test n = 3). Reduced agonist-induced cAMP accumulation in HPRT-deficient SH-SY5Y
(C) and MN9D (F) cells. Cells were stimulated with DMSO (CTL) or forskolin. Cyclic AMP level was evaluated as described in material and methods. The
data are expressed as level of cAMP normalized to protein content. Error bars represent mean 6 SEM of triplicate measurements of two experiments
(n = 6). The asterisks (*p,0.05) represent statistical significance between forskolin treated cells (t-test). (G & H) Altered-CREB-mediated transcriptional
activity in HPRT-deficiency; HEK293 cells lines were infected with lentivirus vector encoding small hairpin against luciferase (HPRT+) and HPRT gene
(HPRT2). Cells were subsequently transfected with pCRE-DD-Zs-Green1 (CREB probe) and then stimulated with DMSO (CTL) or 50 mM Forskolin for
30 min. Figure shows microscopy images of DAPI staining and green fluorescence which is a measure of the overall CREB-related transcriptional
activity. There is diminished green fluorescence in HPRT-deficient cells relative to control cells after stimulation with forskolin. (Bar scale, 100 mm). This
is confirmed by the quantification of the mean fluorescent intensity illustrated in Figure H. Error bars represent mean 6 SEM of duplicate
measurements of two independent experiments. The asterisks (*) represent statistical significance between forskolin treated cells (p,0.05, t-test).
doi:10.1371/journal.pone.0063333.g001
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HPRT and Luciferase Short Hairpin Oligonucleotides and
Knockdown
Short hairpin RNA (shRNA) sequences against the luciferase
and HPRT genes were prepared and transfected as previously
described [4] [7]. HEK293 cells were infected at a multiplicity of
infection (MOI) of approximately 1 with the knockdown
lentivector-sh2hprt (directed against HPRT) or with control
lentivector-shlux (directed against luciferase) as previously de-
scribed [9,10].
Total RNA Isolation and Quantitative PCR Analysis
Total RNA was isolated for QPCR as previously described [7].
Table S1 lists the primers used in this study.
cAMP Assay
Control and HPRT-deficient cells were seeded in serum free
DMEM at a density of 26105 per cm2, and then treated with
vehicle (1% DMSO in PBS) or 1–50 mM of forskolin (SIGMA) for
15 min. In other conditions, cells were pre-treated for 30 min
before the addition of forskolin with 50–200 mM of PDE10A
inhibitor Papaverine, or with 30 mM of PDE4 inhibitor, Rolipram
or with 30 mM of PDE1 inhibitor, Vinpocetin or 30 mM of PDE7
inhibitor, BRL5081 (all from Sigma) or vehicle. Reaction was
terminated by removal of the medium and the subsequent
addition of 0.1M HCl. cAMP accumulation was measured using
‘‘cAMP complete ELISA kit’’ from Enzo-Life Sciences (Cat#
ADI-900-163). Samples were treated according to the manufac-
turer instructions, and the amount of cAMP was normalized to
protein content. Alternatively, the cAMP level in cells was
measured using radioimmunoassay and normalized to the amount
of protein per well as previously described [11,12].
CRE-reporter & Immunocytochemistry
Control or HPRT-knockdown HEK 293 cells were seeded at
density 26105 cells per cm2 and transfected after 24 hr with
pCRE-DD-Zs-Green1 plasmid, a reporter that allows the mea-
surement of cAMP response element binding protein (CREB)
activity (details of the reporter assay can be found at www.
clontech.com cat No 631085). Thirty six hours later, CRE-DD-
Zs-Green1 transfected control and HPRT-deficient cells were then
stimulated with forskolin (50 mM) as described above, in the
presence of 1 mM of shield1. Cells were fixed with 4%
paraformaldehyde and treated with 0.2% Triton-X-100 in 3%
horse serum for 15 minutes and then blocked for one hour in 3%
horse serum in PBS. The cells were then incubated for 15 minutes
in 0.01% of 49,6-diamidino-2-phenylindole (DAPI) (Invitrogen) for
nuclear staining. The resulting cells were mounted with Vecta-
shield media (Vector Laboratories, Burlingame, CA). Fluorescence
was visualized using Olympus BX51 fluorescent microscope with
BP72 Olympus acquisition camera. Images were captured for each
experimental condition and green fluorescence quantified by mean
fluorescent unit using Image J software.
Protein Kinase A (PKA) Assay
Control and HPRT-deficient cells were seeded and treated with
DMSO and forskolin as indicated above. The reaction was
terminated by removal of the medium and subsequent addition of
mammalian protein extraction reagent (M-PER from Thermo-
Scientific) containing a cocktail of protease inhibitors (From
Sigma). PKA activity was measured using ‘‘PKA kinase activity
ELISA kit’’ from Enzo-Life Sciences and normalized to protein
(Cat# ADI-EKS-390A).
Immuno-blot Analysis
Cells were treated as indicated above and lysed using
mammalian protein extraction reagent (M-PER from Thermo-
Scientific) containing the protease inhibitor mixture, 1 mM
PMSF, 1 mM, sodium orthovanadate (Santa Cruz Inc). The cell
lysates were centrifuged 15,000 g at 4uC for 10 minutes and
prepared for immuno-blot analysis with the following primary
antibodies used at dilutions ranging from 1:500 to 1:1000 and
incubated overnight at 4uC: The primary polyclonal rabbit
antibodies against synapsin I, phospho-synapsin I (Ser9), GAPDH
was obtained from (Cell Signaling TechnologyH, CST). Phospho-
PKA substrate (RRXS*/T*) (100G7E) rabbit antibody was also
obtained from CST. Additionally, primary rabbit antibodies
against PDE4B, PDE10A and HPRT were obtained from Abcam.
Goat and rabbit antibodies against PDE7B, b-actin and PDE1C
were obtained from GeneTex, Santa Cruz and Fabgennix,
respectively and secondary IgG antibodies labeled with horserad-
ish peroxidase from Santa Cruz (dilution 1:20000 incubated for
one hour at room temperature). Western-blot signal was quantified
using densitometry Image J software according to the protocol
published at http://openwetware.org/wiki/Bitan:densitometry. b-
actin or GAPDH were used as loading controls.
6-Bnz-cAMP Analog Treatment Assay
control and HPRT-deficient cells seeded in conditions indicated
above were treated with vehicle PBS (control) and up to 200 mM
of N6-Benzoyl adenosine-cAMP for 30 min in serum free
conditions. The reaction was terminated by removal of the
medium and subsequent addition of mammalian protein extrac-
tion reagent (M-PER from Thermo-Scientific) and a cocktail of
protease inhibitors (From Sigma). Cell lysates were processed for
immuno-blot analysis as described previously.
siRNA Experiments
26105 HPRT-deficient MN9D cells in 6 well-plate were exposed
to80pmoleof control (scramble siRNA)orPDE10AsiRNA(directed
to mouse PDE10A) from Santa cruz biotechnology and transfected
according to theestablished transfectionprotocol (http://datasheets.
scbt.com/siRNA_protocol.pdf). Forty eight hours after transfection,
the cells were lysed and processed for protein quantification and
immuno-blot analysis against PDE10 and GAPDH. The siRNA
Figure 2. Reduction of Synapsin I mRNA level in HPRT-deficient
cells. Synapsin I mRNA expression is reduced in HPRT-Deficient
(mutant) MN9D cells. The asterisks (*) represent statistical significance
between control (open bar) and mutant cells (closed bar) (n = 4, p,0.05,
t-test).
doi:10.1371/journal.pone.0063333.g002
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transfected cells (siRNA-CTL and siRNA-PDE10) were also treated
with forskolin as indicated above.
Lentivirus Preparation and HPRT-Reconstitution
Experiment
Lentivirus-based plasmids expressing GFP and HPRT genes
were generated by inserting cDNA for GFP (obtained by PCR
from p-EGFP-N1 cloning vector, from Clontech), and cDNA from
HPRT (from OriGene) into pSin-EF2-Puro (from Addgene) using
SpeI and EcoRI restriction site. pSin-EF2-Puro contains a
constitutively active promoter from human elongation factor and
a puromycin resistance marker for selection of stable transfectants.
VSV-G pseudotyped lentivirus–based vectors expressing GFP, as
well as HPRT were prepared by using HEK 293T cells and were
subjected to the established triple transduction protocol as
previously described [9,13]. HPRT-deficient MND9 cells were
infected at the multiplicity of infection (MOI) of 100 and selected
for puromycin for seven days (1 mg/ml). The HPRT phenotype of
the infected cells was confirmed by growing the cells in 250 mM of
6-thioguanine (6-TG) (SIGMA) and in 16hypoxanthine aminop-
terin thymidine (HAT) medium (from ATCC). The growth of the
GFP-infected HPRT-deficient MN9D cells remains unaltered in
6-TG while it was severely impaired in HAT (data not shown).
Conversely, HPRT-reconstituted MND9 cells were now display-
ing altered growth in 6-thioguanine (data not shown). The HPRT
phenotype of MN9D infected cells was genotypically confirmed
using PCR and Immuno-blot with an HPRT antibody (Abcam).
Statistical Analysis
Statistical analyses were carried out using Kaleidagraph
graphing & data analysis software package (Synergy Software,
Reading Pa). The data are reported as mean +/2 standard error
(SE). Student paired t-tests were performed for control and
experimental groups or One way ANOVA with Tukey post-hoc
test where appropriate. Statistical significance was set at p,0.05.
Results
Mir-181a-mediated Regulation of cAMP/PKA Related
Genes in HPRT-deficient Cells
We have previously demonstrated that HPRT-deficiency
dysregulates the expression of various microRNAs, including
miR-181a in SH-SY5Y human neuroblastoma cell lines, which in
turn targets several neuro-developmental genes [7]. For this study,
we submitted the list of miR-181a target genes to DAVID (Data
Figure 3. Blunted PKA-mediated signaling in HPRT-deficient MN9D cells. (A), Immuno-blot analysis of phospho-PKA-substrate expression
and p-Syn I (Ser9) in response to forskolin exposure. (B), quantification phospho-synapsin relative to the total amount of protein measured as beta-
actin. Error bars represent mean 6 SEM of duplicate measurements of two independent experiments (n = 4). The asterisk (*) represents statistical
significance between forskolin treated cells (p,0.05 t-test). (C&D), Effect of 6-bnz-cAMP on phospho-PKA-substrate and p-Syn I (Ser9) expression in
HPRT-deficient MN9D cells. Data show reduced expression of phospho-PKA-substrates including p-Syn I (Ser9) in HPRT-deficient MN9D cells, after 6-
bnz-cAMP treatment. The quantification of p-Syn relative to beta-actin is seen in figure D. Error bars represent mean 6 SEM of duplicate
measurements of two independent experiments (n = 4). The asterisk (*) represents statistical significance between 6-bnz-cAMP treated cells (p,0.05
t-test).
doi:10.1371/journal.pone.0063333.g003
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annotation for visualization of integrated discovery) [14–16] in
order to identify additional genes and pathways involved in the
regulation of cyclic purine nucleotides pathway. Table S2 shows
some GO terms derived from miR-181a target genes. Among the
GO terms, the ‘‘purine nucleotide metabolic process’’ term contains the
list of genes involved in the cAMP/PKA pathway, such as the
transcription factor CREB that had previously been identified as a
potential target of miR-181a [7].
CREB-mediated Transcriptional Activity is Reduced in
HPRT-knockdown (KD) Cells
To determine the role of CREB in HPRT-deficiency, we
treated human (SH-SY5Y) and mouse (MN9D) control cells and
HPRT-deficient cell lines with forskolin, a direct adenylyl cyclase
activator that increases cAMP accumulation. We found forskolin
increased CREB expression in control cells, but not HPRT-
deficient cells (Fig. 1A & 1B for SH-SY5Y cells and Fig. 1D & 1E
for MN9D cells). The decrease in response correlated to reduced
cAMP accumulation in both human and mouse HPRT-deficient
cell lines (Fig. 1C & Fig. 1F). To show further evidence that
HPRT-deficiency blunts CREB expression, we used a pCRE-DD-
Zs-Green reporter vector (CREB probe) to monitor CREB
activation in control and HPRT-deficient human embryonic
kidney (HEK) 293 cells (control, Lenti-shlux and HPRT-knock-
down Lenti-sh2HRPT). The HPRT-knock-down in HEK293 was
verified by western-blot analysis and show a significant knock-
down of the HPRT gene (Fig.S1), additionally HEK293 HPRT-
knock down cells were also able to grow in 6-thioguanine (data not
presented). The CREB probe (CRE-DD-Zs plasmid) contains
cyclic AMP response elements that bind CREB to induce the
expression of DD-Zs-Green fluorescent gene. We found that
CREB-dependent promoter activity as measured by the level of
green fluorescence intensity was reduced by 50% in HPRT-
knockdown HEK293 cells upon forskolin treatment (Fig. 1G &
1H). HEK293 HPRT-KD cells also produced less cAMP in
response to forskolin (Fig. S2). Together these data show reduced
cAMP accumulation and CREB expression and CREB-transcrip-
tional activity in a variety of HPRT-deficient cells.
HPRT-deficiency Decreases Synapsin I mRNA
In these experiments and all the following ones we examined
cAMP/PKA-related signaling principally in HPRT-mutant
MN9D cell lines made HPRT-deficient by 6-thioguanine muta-
tion/selection that present 0.4% of HPRT enzyme activity [8].
These neuronal cell lines of a dopaminergic lineage have been
used to evaluate dopamine related signaling and function in
HPRT-deficiency and other neurological diseases that affect
dopaminergic neurotransmitter system [17,18]. Therefore, these
cell lines are faithful surrogate model for studying the effects of
purine metabolism deficit caused by HPRT-deficiency on
neuronal signaling functions.
The level of HPRT activity in these cells is metabolically
consistent with the LND phenotype [8]. CREB binds DNA
sequences with cAMP response elements (CRE), which are present
in the promoter of many genes, including tyrosine hydroxylase
(TH) and synapsin I [19,20]. Studies from our laboratory and
other groups have previously reported decreased TH mRNA levels
in HPRT-deficient cells [4,8]. In the current study, we demon-
strate a significant reduction of Synapsin I mRNA level in HPRT-
deficient (mutant) cell lines compared to control (Fig. 2 p,0.05).
These results support the conclusion that HPRT-deficiency
reduces CREB-related transcriptional activity.
HPRT-deficiency Attenuates PKA Activity
In order to unravel the impact of reduced cAMP accumulation
on additional down-stream signaling effectors, we measured PKA
expression and activity in HPRT-deficient MN9D cells. We used a
phospho-PKA substrate (RRXS*/T*) (100G7E) monoclonal
antibody to identify PKA substrates and evaluate the global
pattern of expression of PKA substrates in cells. This antibody
detects peptides and protein containing phospho Ser/Thr residues
with arginine at the 23 and 22 positions. Figure 3A shows a
global reduction of the activity of PKA-substrates in response to
forskolin in HPRT-deficient MN9D cells compared to control,
which corresponds to decreased PKA activity (Fig. S3). PKA is
known to phosphorylate several protein substrates relevant to
neural functioning, including Synapsin I [21–23]. Figures 3A & 3B
demonstrate that there is significantly less phosphorylated Syn I
(Ser9) protein in HPRT-deficient MN9D cells after forskolin
Figure 4. Increased PDE10A protein expression in HPRT-deficient MN9D cells. (A&B) Immuno-blot and quantification analysis for various
PDEs that can affect cAMP/PKA signaling. Data show that the expression of PDE1C, PDE4B, and PDE7B are similar between control (parent) and HPRT-
deficient (mutant) MN9D cell lines. Expression of PDE10A protein is significantly increased in HPRT-deficient cells. Error bars represent mean6 SEM of
duplicate measurements of two independent experiments (n = 4). The asterisk (*) represents the statistical significant between the control (open bars)
and HPRT-deficient (closed bars) MND9 cells (p,0.05 t-test).
doi:10.1371/journal.pone.0063333.g004
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Figure 5. PDE10 inhibition restores PKA-mediated expression. (A & B), immuno-blot and quantification analysis of p-Syn (Ser9), data show
that the lower expression of phospho-PKA substrate and p-Syn (Ser9) in response to forskolin treatment in HPRT-deficient MN9D cells is restored in
the presence of Papaverine (200 mM). Error bars represent mean 6 SEM of duplicate measurements of two independent experiments (n = 4). The
asterisks (*) represent statistical significance between forskolin treated cells without papaverine treatment (p,0.05, t-test). (C & D), immuno-blot and
quantification analysis of PDE10A expression after transfection of HPRT-deficient MN9D cells with siRNA directed to the mouse PDE10 gene. The data
show lower expression PDE10A protein in cells transfected with siRNA-PDE10A relative to cells transfected with scramble control siRNA (siRNA-CTL).
Error bars represent mean 6 SEM of duplicate measurements carried out independently twice (n = 4). The asterisks (*) represent the statistical
HPRT-Deficiency Dysregulates cAMP/PKA
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treatment compared to control. Our data also show that HPRT-
deficient MN9D cells display reduced global pattern of PKA-
mediated phosphorylation in response to the PKA-selective cell
permeable cAMP analog, N6-Benzoyladenosine-39,59-cyclic
monophosphate (6-bnz-cAMP, 200 mM) (Fig. 3C); in addition,
the level of phospho-synapsin expression is only marginally
increased compared to control cells (Fig. 3C & 3D). To show
whether the reduction of PKA-mediated synapsin I phosphoryla-
tion is only true for HPRT-deficient MN9D cells, we also carried
out analysis of phospho-synapsin in HPRT-deficient human SH-
SY5Y cells. Our data show blunted expression in response to
forskolin can also be seen in SH-SY5Y (Fig. S4).
Increased of Phosphodiesterase 10 (PDE10) Expression
with HPRT-deficiency
To identify possible mechanisms by which HPRT-deficient cells
attenuate PKA-related signaling, we noted several genes that are
potential targets for miR-181a could regulate the level of cAMP
signaling, namely adenylyl cyclase (AC) 1 and 9 as well as PDE10A
(see Table S3). Interestingly, PDEs, including PDE10A, have
previously been shown to be highly expressed in the brain, and are
implicated in other neurological diseases [24,25]. To examine the
possible role of PDE10 in the reduction of cAMP/PKA-mediated
signaling associated with HPRT-deficiency, we examined the
expression of a number of PDEs that are known to be highly
expressed in the brain and regulate cAMP (PDE1C, PDE4B,
PDE10A, PDE7B) in both control and HPRT-deficient MN9D
cells [26,27]. Figure 4 shows that only PDE10 expression is
significantly increased in HPRT-deficient MN9D cells (Fig. 4A
&4B). To investigate the contribution of increased PDE10 to the
reduced cAMP/PKA-signaling associated with these HPRT-
deficient cells, we examine substrate expression, including
phospho-synapsin, in the presence of papaverine a PDE10 specific
inhibitor [28,29]. Papaverine significantly increased the level of
PKA expression and phospho-PKA substrates expression, includ-
ing phospho-synapsin, both before and after forskolin treatment
(Figure 5A, B). In parallel, papaverine restored cAMP production
accumulation in HPRT-deficient cells (data not shown). Increased
phospho-PKA substrates were also seen in the presence of IBMX,
a PDE non-specific inhibitor (data not shown), however not in
presence other PDEs inhibitors such as Rolipram (PDE4, 30 mM),
Vinpocetine (PDE1, 30 mM) and BRL50481 (PDE7, 50 mM) (See
Figure S5). Although papaverine is used as PDE10 inhibitor, it is
also known to have a number of non-specific effects [30].
Therefore, we used siRNA directed specifically to the mouse
PDE10A gene to decrease PDE10A expression in HPRT-deficient
MN9D cells. PDE10A protein expression was reduced in HPRT-
deficient MN9D cells transfected with PDE10A siRNA compared
to scramble (control) siRNA (Figure 5C, D). The decrease of
PDE10A gene expression by siRNA-PDE10 in the HPRT-
deficient cells significantly increased the expression of phospho-
PKA substrates, including phospho-synapsin (Fig. 5E and 5F).
Restoration of HPRT Expression and its Impact of
Synapsin Expression and PKA-related Signaling
To confirm the association between HPRT-deficiency and the
decreased Synapsin I and PKA activity, we reconstituted HPRT
expression and activity in HPRT negative MN9D cells. MN9D
cells were transfected with lentivirus vectors encoding for GFP
(transfection control) or the HPRT gene (see figure S6 in
supplemental data). The HPRT-reconstituted MN9D mutant cells
increased sensitivity to growth in culture medium containing 6-
thio-guanine, (250 mM) unlike their GFP infected counterparts
(data not shown). The HPRT-reconstituted MN9D cells displayed
significant (p,0.05, t-test) between the control (open bar, siRNA-CTL) and siRNA-PDE10A transfected cells (closed bar). This significant reduction of
PDE10A protein contributes to the enhanced expression of phospho-PKA-substrates including p-Syn observed in (E & F). Error bars represent mean
6 SEM of duplicate measurements of two independent experiments (n = 4). The asterisk (*) represents the statistical significant (p,0.05, t-test)
between the siRNA-CTL and siRNA-PDE10A HPRT-deficient transfected MND9 cells treated with forskolin.
doi:10.1371/journal.pone.0063333.g005
Figure 6. Effect of HPRT-rescue on cAMP/PKA signaling. Immuno-blot and densitometry quantification analysis of Syn 1and phospho-Syn I (A,
B & C). Data show that the lower expression of Synapsin I protein in response to forskolin treatment in HPRT-deficient MN9D cells is abrogated in
HPRT-reconstituted MN9D cells (B). p-Syn I (Ser9) expression in HPRT-reconstituted cells is partially restored (C). Error bars represent mean 6 SEM of
duplicate measurements of two independent experiments (n = 4). The asterisk (*) represents statistical significance (p,0.05) between forskolin
treated cells control versus HPRT-deficient cells, the double asterisks (**), between forskolin-treated HPRT-deficient cells versus forskolin-treated
HPRT-reconstituted cells (ANOVA and Tukey, post-hoc test).
doi:10.1371/journal.pone.0063333.g006
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a noticeable increase in Syn I protein expression compared to
HPRT-deficient MN9D cells (Fig. 6A–6B); however we observed
only partial restoration of phospho-synapsin expression (15% of
the control, Fig. 6C). Furthermore, the rescue of HPRT-activity
did not fully restore the expression of phospho-PKA substrates or
the increased expression of PDE10 in HPRT-deficient MN9D cell
lines (data not shown).
Discussion
We have previously shown that the dysregulation of miR-181a in
HPRT-deficient cells affect theexpressionofkey transcription factors
that drive neuronal development [7]. The current study expands
upon this previous investigationbasedon thepremise that the actions
of this microRNA extend to pathways beyond neurodevelopment to
affect expression and signaling pathways of mature neurons. We
Figure 7. Schematic of the possible mechanisms by which HPRT-deficiency via blunting of cAMP/PKA signaling leads to the neural-
related LND phenotype. HPRT-deficiency is primarily a purine metabolism deficiency that affects the cellular purine pools. The deficit in purine
pools causes changes in expression and activity of PDE and/or AC reduces cAMP production. We propose that the cAMP deficit in HPRT-deficient
causes a reduction in CREB and thereby expression of neural genes such as Synapsin I. The decrease in PKA activity blunts phosphorylation of
substrates, such as p-Syn I (Ser9), which is known to affect neurotransmitter release. We conclude HPRT-deficiency via inhibiting cAMP/PKA signaling
could affect neurotransmission and neuro-modulation that underlie the neurological phenotype in LND.
doi:10.1371/journal.pone.0063333.g007
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identified thatmiRNA-181amayregulate theubiquitously expressed
transcription factor CREB, whose the role in neuronal pathway and
function is widely documented [31,32]. We demonstrate reduced
expression of CREB in HPRT-deficient cells that correlated with
reduced cAMP accumulation (Fig. 1). These data correlate with
previous studies that have shown that HRPT-deficiency is accom-
panied by decreased activity of AC, which catalyzes the formation of
cAMP [33]. A more recent study demonstrated the impaired
expression and function of AC2 in HPRT-deficient rat B103
neuroblastoma [34]. Our data further support the role of dysfunc-
tional cAMP-signaling in HPRT-deficiency.
As a transcription factor, CREB regulates the expression of a
wide number of genes, such as the Synapsin gene which possesses
a CRE consensus sequence in its promoter [35]. We demonstrate
blunted expression of Synapsin I mRNA in HPRT-deficient
MN9D cells (Fig. 2). Synapsin I, along with Synapsin II and
Synapsin III are phosphoproteins that bind to the cytosolic surface
of synaptic vesicles. Their role is to store and release neurotrans-
mitters. Our current data suggest a role for Synapsin I in the
etiology of HPRT-deficiency; its reduced expression may contrib-
ute to the alteration of the dopaminergic neurotransmitter system
in LND [2,36]. The reduction in agonist induced cAMP
accumulation in HPRT-deficient cells led us to examine PKA-
mediated signaling; since the cellular actions of cAMP are known
to be mediated, at least in part, by PKA. In the brain, PKA
phosphorylates many targets important for proper neuronal
function [37]. Consequently, consistent with the reduction in
cAMP production in HPRT-deficient cells, we found blunted
PKA-mediated signaling in response to forskolin (Fig. 3). We
report for the first time a global reduction of phospho-PKA-
substrates including phospho-synapsin in HPRT-deficient MN9D
cells both before and after agonist stimulation. We have
demonstrated that the reduction in the expression of phospho-
synapsin is also seen in HPRT-deficient human neuroblastoma
cells (Fig. S4). Consistent with our findings is the observation of a
global reduction of phospho-PKA-substrate expression in HPRT-
deficient human induced pluripotent stem cells (Zhu and
Friedmann, unpublished data). We also uncovered a decrease in
the expression of many other PKA substrates in HPRT-deficient
human and mouse neuroblastoma cell lines, including tyrosine
hydroxylase (TH) (Ser40) and DARPP-32 (Thr34) (data not
shown) that are also important effectors of neuronal function
[28,38,39]. The reduced expression of these PKA dependent
phospho-proteins, including synapsin, may have implications for
LND neuropathophysiology.
Within the cell, the level of cAMP and thus PKA activity is
mediated by a balance of formation by adenylyl cyclase, and
degradation by PDEs [40]. From the list of potential target genes
for miR-181A we found PDE10A to be potentially unregulated
and therefore we further investigated the role of this PDE isoform
in our cellular model (Table S3). While PDE3B and PDE5 are also
among the potential targets of miR-181a, we did not examine their
role in the cAMP/PKA dysregulation, principally because PDE3B
expression in the brain is mostly known be associated with
hypothalamic functions [41–43], while PDE5 controls cyclic GMP
(cGMP) signaling. In the context of this study, and as PDE10 is
known to hydrolyze both cAMP and cGMP, our data suggest a
role for cGMP-dependent signaling in HPRT-deficiency. In fact,
we have observed blunted production of cGMP along with
dysregulated expression of protein kinase G (PKG) related
signaling in HPRT-deficient MN9D cells upon exposure to nitric
oxide (NO) donor Sodium nitroprusside (SNP) (Guibinga et al.
unpublished data). We are currently investigating the significance
of these findings in HPRT-deficiency and in relation, not only to
PDEs dysregulation, but also uric acid, a known effector of NO
production, which could indirectly influence cGMP/PKG signal-
ing in HPRT-deficient cells.
We analyzed the expression of other PDEs known to hydrolyze
cAMP, suchasPDE4andPDE7,but found thesedidnot significantly
change between control and HPRT-deficient cells (Fig. 4).We also
examined the expression of PDE1C, a PDE1 isoform known to be
expressedathigher level thanPDE1AorPDE1Bin thedopaminergic
regions of substantia nigra [44]; like for PDE4 and PDE7, we did not
observeasignificantdifferenceinPDE1Cexpressionbetweencontrol
and HPRT-deficient cell lines (Fig. 4). Conversely, we found that
HPRT-deficient cells had increased expression of PDE10A, suggest-
ing enhanced PDE10 activity. We have also found an increase in
PDE10 mRNA expression in fibroblasts cells derived from LND
patients compared to control (Figure S7).Mindful that fibroblast and
neuronal cells have a different genomicmake up, in absence of brain
tissues derived from LND patients, fibroblast cells have often
validated dysregulated expression of genes or microRNAs relevant
to brain functions ([3,7]. Of interest, PDE10 expression is highly
enriched in the striatum [45], part of the forebrain known to be
affected inLND.Wehave shownan increase of PDE10 transcripts in
striatal tissue derived from HPRT knockout (HPRTKO) relative to
wild-type (Guibinga, unpublished data). All together, these results
support a role for PDE10A in the etiology of LND. These data also
suggest cautionas the full dynamicofPDEsexpression inLNDbrains
and HPRTKOmouse striatum remain to be determined.
Papaverine, a PDE10 specific inhibitor, and siRNA targeted to
PDE10A reversed the decrease in expression of phospho-PKA-
substrates, including phospho-synapsin, in HPRT-deficient MN9D
cells. Together these data suggest a key role for PDE10A in the
dysfunctional cAMP signaling in these HPRT-deficient cells.
Inhibitors of PDE10 have been shown to increase CREB phosphor-
ylation inbothmouse striatumin vivoandrat striatal neurons in vivo
[46,47].Moreover, newgenerationofPDE10 inhibitorsmorepotent
andmore specific than papaverine are currently under investigation
as novel antipsychotic agents [24,48]. Pending the full characteriza-
tion of PDEs expression and activity profile in the basal ganglia of
LND patients, these new generations of PDE10 inhibitors could
potentially be evaluated as therapeutic agents for LND; a disease for
which there are still limited therapeutic options. In themeantime the
unraveling of cyclic nucleotide regulation dynamic in the striatum of
HPRTKO mouse through pharmacological manipulation could
provide initial cues on the potential applicability of PDE-based
therapy for LND.
Until now, only few studies have examined the role that cyclic
nucleotides play in the etiology of HPRT-deficiency. Two of these
investigations have documented significant changes in cAMP level
and ACs in cell membranes from HPRT-deficient cell lines
[33,34]. Although, these two studies have been immensely
informative in linking HPRT-deficiency to cyclic AMP related
functions, their data did not correlate these cAMP-alterations to
signaling pathways known to be activated by cAMP, nor did they
demonstrate their relevance to neuronal functioning. Our
investigation investigates for the first time the role of PDEs in
HPRT-deficient cells; in addition, our study provides a novel angle
on the cyclic nucleotides regulation in HPRT-deficiency and
suggests the impact they may have of neuronal function.
To investigate further how HPRT-deficiency affects cAMP/
PKA signaling, we restored HPRT expression and activity; our
data show the restoration of Syn I expression in HPRT-
reconstituted cells (Fig. 6A & 6B). In contrast, we only partially
reversed the reduced level of phospho-synapsin I in HPRT-
reconstituted MN9D cells. These data show that the reduced
expression of synapsin mRNA and protein, as shown in figures 2, 3
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and 5, is only partially responsible for the reduced phospho-
synapsin. We propose that the derangements in purine metabolism
caused by HPRT-deficiency can lead to accumulation of
metabolites that affect PKA-signaling, and those are not neces-
sarily reversible by restoration of HPRT expression and activity.
Our findings are consistent with previous research carried out in
HPRT-deficient PC12 cell culture; where HPRT-deficiency was
shown to affect dopamine content in these cells, while the rescue of
HPRT failed to restore the dopamine level to normal [49].
All together our data suggests a novel mechanism by which in
HPRT-deficiency contributes to neural dysfunction. We propose
blunted CREB-mediated transcriptional and cAMP/PKA signal-
ing, possibly due in part to increased PDE10A, provides a
rationale and coherent framework of a possible mechanism by
which HPRT-deficiency affects the neuro-pathogenesis of LND.
As depicted in Figure 7, the purine metabolism alterations caused
by HPRT-deficiency engenders deficits in cyclic AMP regulation
which in turn affect PKA signaling, among other phospho-
synapsin expression. Blunted phospho-synapsin expression likely
impacts dopamine release, thus neurotransmission and neuro-
modulation thereby causing the neurological phenotype in LND.
Supporting Information
Figure S1 HPRT-knockdown in HEK293 cells. Western
blot analysis of HEK293 cells infected with Lentivector-sh2hprt
expressing the small hairpin targeted to HPRT (SH2-HPRT, right
lane) or with control vector Lentivector-shlux targeted against
luciferase (WT-LUX, left lane). Figure shows a significant
reduction of HPRT protein in Lentivector-sh2prt-transduced cells.
(TIF)
Figure S2 Reduced agonist induced cAMP accumulation
in HPRT-deficient cells. (A) HPRT-deficient human 293
(SH2-HPRT) cell lines and their equivalent control cell lines (Sh-
LUX) were stimulated with DMSO (CTL) and forskolin 50 mM
15 min. cyclic AMP level was evaluated as described in material
and methods. The data are expressed as level of cAMP normalized
to protein content. Error bars represent mean 6 SEM of duplicate
measurements of two independent experiments (n = 4). The
asterisks (*p,0.05) represent statistical significance between
forskolin treated cells (t-test).
(TIF)
Figure S3 HPRT-deficiency blunts cyclic AMP-depen-
dent protein kinase (PKA) activity. Figure shows decreased
PKA activity in HPRT deficient MN9D cells. The data are
expressed as normalized level of PKA activity relative to total
protein content. Error bars represent mean 6 SEM of duplicate
measurements of two independent experiments (n = 4). The
asterisks represent statistical significance between forskolin treated
cells (*p,0.05, t-test).
(TIF)
Figure S4 Reduced phospho-synapsin in human HPRT-
deficient SH-SY5Y cells. (A & B), immuno-blot and
quantification analysis of p-Syn (Ser9), data show that the lower
expression of syn I and p-Syn (Ser9) in response to forskolin
treatment in HPRT-deficient SH-SY5Y cells. Error bars represent
mean 6 SEM of duplicate measurements of two independent
experiments (n = 4). The asterisk (*) represent statistical signifi-
cance between forskolin treated cells (*p,0.05, t-test).
(TIF)
Figure S5 The PDE1, PDE4 and PDE7 inhibitors
vinpocetine, rolipram and BRL5081, respectively do
not improve phospho-synapsin p-Syn (Ser9) expression
in HPRT-deficient MN9D cells. (A, B & C) immuno-blot of
control and HPRT-deficient MN9D cells after pre-treated with the
indicated PDEs inhibitors before forskolin treatment (see meth-
ods).
(TIF)
Figure S6 HPRT-rescue in HPRT-deficient MN9D cells.
(A) HPRT mRNA in MN9D deficient cells infected with
lentivector encoding the GFP gene (GFP) or the HPRT gene
(HPRT). The data show a significant increase of HPRT gene
expression over the GFP expressing cells (41 fold). Error bars
represent mean 6 SEM of duplicate measurements (n = 2). The
asterisk (*) represents statistical significance (p,0.05, t-test)
between GFP-infected cells and HPRT-infected cells. (B &C),
reconstitution of HPRT expression in HPRT-deficient MN9D
cells. Immuno-blot and quantification analysis of HPRT protein
expression in control MN9D cells (1), HPRT-deficient MN9D cells
(2), HPRT-lentivirus infected HPRT-deficient MN9D cells (3),
and GFP-lentivirus infected HPRT-deficient MN9D cells (4).
Error bars represent mean 6 SEM of triplicate measurements
(n = 3). The asterisk (*) represents the statistical significance
(p,0.05) between the control and HPRT-deficient MND9 cells;
while the double asterisks **represent statistical significance
between GFP and HPRT-infected cell cells (p,0.05, t-test).
(TIF)
Figure S7 Gene expression profile of PDE10A in fibro-
blasts cells from normal (CTL) mildly (LNV) and
severely (LND) affected HPRT-deficient patients. (A)
DCT value of each category of patients, showing that LND
subjects have significantly lower DCT than control (CTL); leading
to significantly higher fold change in PDE10 mRNA level (B). (*
p,0.05, ANOVA).
(TIF)
Table S1 List of primers.
(TIF)
Table S2 Functional annotation clustering pertaining to
purine pathways. The table includes GO terms related to
‘‘purine metabolism’’ derived from miR-181a potential target
genes and selected from target-combo and targetScan database.
GO terms were extracted using DAVID as previously described
(Guibinga et al. 2012). Highlighted is the GO term ‘‘purine
nucleotide metabolic process’’.
(TIF)
Table S3 List of potential miR-181a target genes
derived from GO term related to ‘‘purine nucleotide
metabolic process’’. The table includes several genes known to
regulate cAMP/PKA, such as PDE10.
(TIF)
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